Zepbound®

Zepbound® is the brand name for tirzepatide manufactured by Eli Lilly, FDA-approved specifically for chronic weight management in adults with obesity or overweight with weight-related conditions. Unlike Mounjaro® (approved for diabetes), Zepbound® is formulated and indicated specifically for weight loss.

Zepbound® features a unique dual-action mechanism, activating both GLP-1 and GIP receptors to provide superior appetite control and metabolic support. At altRx, Zepbound® is prescribed through licensed clinicians who create personalized treatment plans with ongoing telehealth support throughout your weight loss journey.

Both Zepbound® and Mounjaro® contain tirzepatide and are manufactured by Eli Lilly, but they differ in FDA approval and indication. Mounjaro® is approved for type 2 diabetes management, while Zepbound® is specifically approved for chronic weight management.

Both use the same dosing schedule (up to 15mg weekly) and have identical active ingredients. The main difference is the intended use and prescribing indication. Your clinician will determine which is appropriate based on your medical history—whether you have diabetes, pre-diabetes, or are seeking weight loss without diabetes.

Zepbound®'s dual-receptor mechanism represents the most advanced approach to medical weight management. By activating both GLP-1 and GIP receptors, it addresses weight loss through multiple complementary pathways. GLP-1 suppresses appetite, slows gastric emptying, and improves insulin sensitivity. GIP enhances metabolic rate, improves fat utilization, and may reduce fat storage.

The landmark SURMOUNT clinical trial program demonstrated exceptional results: participants taking the highest dose (15mg) lost an average of 22.5% of their body weight—the highest efficacy ever seen in a weight loss medication trial. Beyond weight loss, Zepbound® improved cardiovascular risk factors, inflammation markers, and overall metabolic health.

Most users report a dramatic reduction in 'food noise'—the constant mental preoccupation with food and eating. Appetite decreases significantly within the first week, and cravings for high-calorie foods tend to fade. Meals become satisfying with much smaller portions, and the desire to snack virtually disappears for many users.

Initial side effects may include nausea, digestive changes, or mild fatigue—these typically resolve within 2-4 weeks. The dual-action mechanism often provides more sustained appetite control throughout the day compared to single-hormone medications. Dosing starts at 2.5mg weekly and increases gradually every 4 weeks, minimizing side effects while building toward maximum effectiveness. Users consistently report steady, significant weight loss alongside improved energy and metabolic health.

Administration: Once-weekly subcutaneous injection using pre-filled AutoInjector pen with built-in needle
Dosing: Escalates gradually: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg (max), increasing every 4 weeks based on tolerance
Storage: Refrigerate unused pens (36-46°F); can be kept at room temperature (up to 86°F) for up to 21 days before first use
Manufacturer: Eli Lilly and Company